Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 24, 2026

AI-Enabled Edge and Autonomous Systems Take Center Stage

View original at globenewswire.com
AI-Enabled Edge and Autonomous Systems Take Center Stage AUSTIN, Texas, Feb…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • As an Army-sponsored vendor participating in TiC 2.0, we have a valuable opportunity to directly showcase NODE's unique ability to support Army units by providing our real-time explosive threat detection and mapping capabilities for soldiers on the ground

    80% confidence
  • We are especially excited to integrate our AI-powered detection data into the widely fielded GeoSuite platform, building a novel solution that can rapidly deliver greatly enhanced operational situational awareness to the teams taking part in this critical technology event

    80% confidence
  • Initial government revenue validates our technology platform and positions Safe Pro for continued operational expansion

    80% confidence
  • We believe global demand for AI-enabled drone intelligence and American defense technology is entering a sustained growth cycle

    80% confidence
  • The first quarter of 2026 represents a transformational period for Safe Pro

    80% confidence
  • Safe Pro believes it is entering a commercial and government adoption inflection point, transitioning from development-stage operations into scaling revenue generation and opportunities to access additional government programs

    80% confidence
  • Tactical edge AI enables faster reaction times and improves resilience in high-threat scenarios

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
AI-Enabled Edge and Autonomous Systems Take Center Stage — Source | Via News | Via News